Azelnidipine Anti-Coronary Atherosclerotic Trial in Hypertensive Patients by Serial Volumetric IVUS Analysis(ALPS-J)

Juntendo University

Status and phase

Completed

Phase 4

Conditions

Hypertension

Coronary Atherosclerosis

Treatments

Drug: Calcium channel blockers (amlodipine, azelnidipine)

Study type

Interventional

Funder types

Other

Identifiers

NCT00294567

JHF-17NOV2005

Details and patient eligibility

About

In patients with hypertension who undergo elective PCI, the effects of long-term administration of Calblock (azelnidipine) on plaque volume will be determined quantitatively by 3D-IVUS and compared with those of amlodipine besilate (Norvasc or Amlodin).

Full description

Clinical studies have demonstrated that calcium antagonists can reduce cardiovascular events in patients with coronary artery disease. Recently, suppression of the development of coronary atherosclerotic plaque by calcium antagonists has been reported as one of the mechanisms involved. Thus, calcium antagonists have been promising strategy for preventing the progression of the coronary atherosclerosis. Various calcium antagonists are clinically available at present and these drugs may differ from each other with respect to the anti-atherosclerotic effects. Consequently, we plan to perform the ALPS-J study to compare the effects of two long-acting calcium antagonists, azelnidipine and amlodipine, on plaque quantitatively by IVUS. In this study, azelnidipine (16 mg/day) or amlodipine besilate (5 mg/day) will be administered to patients with hypertension for 48 weeks after elective PCI. The plaque volume will be measured in each patient by IVUS at the time of PCI and 48 weeks after PCI. Percent change in plaque volume from the baseline value will be used as the primary endpoints for evaluation of efficacy. We plan to enroll 100 patients in each group for a total of 200 patients.

Enrollment

199 patients

Sex

All

Ages

20 to 79 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age: Between 20 and 79 years (at the time of giving informed consent).
Sex: Either sex.
Admission status: Outpatients.
Patients requiring treatment for hypertension according to the JSH 2004 hypertension therapy guidelines before beginning this study
Patients who have not used any calcium antagonists for at least 4 weeks before the beginning of this study.
Patients who are scheduled to undergo elective PCI.

Exclusion criteria

Patients with acute coronary syndrome (ACS).
Patients who have experienced Q-wave myocardial infarction within 4 weeks before beginning this study.
Patients with renal dysfunction (serum creatinine >2.0 mg/dL).
Patients in whom PCI is unsuccessful.
Patients with cardiogenic shock.
Patients with moderate or severe congestive heart failure.
Patients with 50% or more stenosis of the main trunk of the left coronary artery.
Patients with other problems whom the investigator considers unsuitable for this study.